162 related articles for article (PubMed ID: 35198796)
21. The Integrated Web Portal for Escalation with Overdose Control (EWOC).
Wang H; Tighiouart M; Huang SC; Berel D; Cook-Wiens G; Bresee C; Li Q; Rogatko A
Open Med Inform J; 2013; 7():18-23. PubMed ID: 23847696
[TBL] [Abstract][Full Text] [Related]
22. A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.
Diniz MA; Kim S; Tighiouart M
J Probab Stat; 2018; 2018():. PubMed ID: 30906326
[TBL] [Abstract][Full Text] [Related]
23. Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity models.
Pantoja K; Lanke S; Munafo A; Victor A; Habermehl C; Schueler A; Venkatakrishnan K; Girard P; Goteti K
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1371-1381. PubMed ID: 35852048
[TBL] [Abstract][Full Text] [Related]
24. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
Tighiouart M; Rogatko A; Babb JS
Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
[TBL] [Abstract][Full Text] [Related]
25. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
James GD; Symeonides S; Marshall J; Young J; Clack G
BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
[TBL] [Abstract][Full Text] [Related]
26. A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials.
Chen Z; Krailo MD; Azen SP; Tighiouart M
Contemp Clin Trials; 2010 Sep; 31(5):473-82. PubMed ID: 20609419
[TBL] [Abstract][Full Text] [Related]
27. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling.
Su X; Li Y; Müller P; Hsu CW; Pan H; Do KA
Pharm Stat; 2022 Nov; 21(6):1149-1166. PubMed ID: 35748220
[TBL] [Abstract][Full Text] [Related]
28. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
[TBL] [Abstract][Full Text] [Related]
29. Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile.
Chen Z; Li Z; Zhuang R; Yuan Y; Kutner M; Owonikoko T; Curran WJ; Kowalski J
PLoS One; 2017; 12(1):e0170187. PubMed ID: 28125617
[TBL] [Abstract][Full Text] [Related]
30. Adaptive dose-finding studies: a review of model-guided phase I clinical trials.
Iasonos A; O'Quigley J
J Clin Oncol; 2014 Aug; 32(23):2505-11. PubMed ID: 24982451
[TBL] [Abstract][Full Text] [Related]
31. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
Zhao D; Zhu J; Wang L
Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
[TBL] [Abstract][Full Text] [Related]
32. Phase I dose-escalation oncology trials with sequential multiple schedules.
Günhan BK; Weber S; Seroutou A; Friede T
BMC Med Res Methodol; 2021 Apr; 21(1):69. PubMed ID: 33853539
[TBL] [Abstract][Full Text] [Related]
33. Bayesian dose escalation in oncology with sharing of information between patient populations.
Broglio KR; Sandalic L; Albertson T; Berry SM
Contemp Clin Trials; 2015 Sep; 44():56-63. PubMed ID: 26173185
[TBL] [Abstract][Full Text] [Related]
34. Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics.
Gerard E; Zohar S; Thai HT; Lorenzato C; Riviere MK; Ursino M
Biometrics; 2022 Mar; 78(1):300-312. PubMed ID: 33527351
[TBL] [Abstract][Full Text] [Related]
35. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.
Cheng JD; Babb JS; Langer C; Aamdal S; Robert F; Engelhardt LR; Fernberg O; Schiller J; Forsberg G; Alpaugh RK; Weiner LM; Rogatko A
J Clin Oncol; 2004 Feb; 22(4):602-9. PubMed ID: 14966084
[TBL] [Abstract][Full Text] [Related]
36. A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Harvey RD; Owonikoko TK; Lewis CM; Akintayo A; Chen Z; Tighiouart M; Ramalingam SS; Fanucchi MP; Nadella P; Rogatko A; Shin DM; El-Rayes B; Khuri FR; Kauh JS
Br J Cancer; 2013 Mar; 108(4):762-5. PubMed ID: 23322195
[TBL] [Abstract][Full Text] [Related]
37. A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages.
Jiménez JL; Zheng H
Biom J; 2023 Oct; 65(7):e2200288. PubMed ID: 37199700
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of Bayesian optimal interval design by accounting for overdose and underdose errors trade-offs.
Sadachi R; Sato H; Fujiwara T; Hirakawa A
J Biopharm Stat; 2023 Nov; ():1-20. PubMed ID: 37966109
[TBL] [Abstract][Full Text] [Related]
39. Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
Tighiouart M; Piantadosi S; Rogatko A
Stat Med; 2014 Sep; 33(22):3815-29. PubMed ID: 24825779
[TBL] [Abstract][Full Text] [Related]
40. Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials.
Jiménez JL; Tighiouart M
J R Stat Soc Ser C Appl Stat; 2022 Nov; 71(5):1996-2013. PubMed ID: 36779084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
